Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol On Track For Growth In 2007 Despite Pargluva Setback

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol is reallocating resources toward existing products and aiming to reach growth targets through other pipeline candidates following the delay and possible termination of muraglitazar.
Advertisement

Related Content

Bristol, Sanofi Pledge To Defend Plavix Patent In Face Of Potential “At Risk” Launch
Bristol, Sanofi Pledge To Defend Plavix Patent In Face Of Potential “At Risk” Launch
Bristol To Consider Sales Force Cuts Following Pargluva Delay
Bristol To Consider Sales Force Cuts Following Pargluva Delay
Orencia Launch Anticipated By Bristol In Early 2006
Pargluva Development May Be Terminated By Bristol, Merck
Pargluva Development May Be Terminated By Bristol, Merck
Novartis Purchases Bristol's Consumer Business

Topics

Advertisement
UsernamePublicRestriction

Register

PS061182

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel